May 30, 2019 09:22 AM EDTUpdated May 31, 08:28 AM
Bioregnum
AI
Opinion

Let's talk AI: Top R&D ex­ecs tack­le where we are and where we're head­ed with this cru­cial new tech­nol­o­gy

As a biotech ex­ec with a back­ground in com­pu­ta­tion­al chem­istry, Rosana Kapeller has been watch­ing the hub­bub over ar­ti­fi­cial in­tel­li­gence and ma­chine learn­ing in bio­phar­ma …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times